Altamira Therapeutics Ltd. (CYTO) Financials

CYTO Assets vs Liabilities

DateAssetsLiabilities
June 30, 2023 6.9 million 8.9 million
March 31, 2023 6.9 million 16.0 million
Dec. 31, 2022 6.8 million 15.8 million
Sept. 30, 2022 6.5 million 15.0 million

CYTO Free Cash Flow and Stock based compensation

No data available :(

CYTO Net Income

No data available :(

CYTO Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2023 55138 - 451655
March 31, 2023 16843 - -
Dec. 31, 2022 - - 499134
Sept. 30, 2022 15786 - -

CYTO Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2023 4.7 million
March 31, 2023 ?
Dec. 31, 2022 63815
Sept. 30, 2022 ?

CYTO Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2023 - 2.8 million - -
March 31, 2023 - - - -
Dec. 31, 2022 - - - -
Sept. 30, 2022 - - - -

CYTO Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2023 128631 331530
March 31, 2023 - -
Dec. 31, 2022 - -
Sept. 30, 2022 - -

CYTO

Price: $0.30

52 week price:
0.30
7.38

Earnings Per Share: 1.82 USD

P/E Ratio: 0.28

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: Bermuda

Volume: 22400

Market Capitalization: 2.0 million

Links: